Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?
Feb 17
Have your own idea? Try our Stock Screener
Chinese (SSE) Biotech Industry Analysis
UpdatedFeb 22, 2025
DataAggregated Company Financials
Companies72
- 7D2.1%
- 3M-0.4%
- 1Y-10.1%
- YTD7.4%
In the last week, the Biotech industry is up 4.1%, with Chongqing Zhifei Biological Products leading the way, up 5.3%. In contrast, the industry has lost 9.7% in the last 12 months. Looking forward, earnings are forecast to grow by 42% annually.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 22 Feb 2025 | CN¥862.5b | CN¥136.0b | CN¥10.8b | 35x | 80.2x | 6.3x |
| Mon, 20 Jan 2025 | CN¥800.1b | CN¥136.0b | CN¥10.8b | 32.7x | 74.4x | 5.9x |
| Wed, 18 Dec 2024 | CN¥867.3b | CN¥136.0b | CN¥10.8b | 33.5x | 80.6x | 6.4x |
| Fri, 15 Nov 2024 | CN¥941.2b | CN¥141.7b | CN¥11.2b | 37.9x | 84x | 6.6x |
| Sun, 13 Oct 2024 | CN¥892.8b | CN¥154.1b | CN¥14.5b | 36x | 61.8x | 5.8x |
| Tue, 10 Sep 2024 | CN¥756.7b | CN¥154.2b | CN¥14.5b | 30.6x | 52.1x | 4.9x |
| Thu, 08 Aug 2024 | CN¥834.7b | CN¥161.2b | CN¥17.3b | 31.3x | 48.3x | 5.2x |
| Sat, 06 Jul 2024 | CN¥822.1b | CN¥161.1b | CN¥17.3b | 32.1x | 47.5x | 5.1x |
| Mon, 03 Jun 2024 | CN¥906.1b | CN¥161.1b | CN¥17.3b | 35.3x | 52.4x | 5.6x |
| Wed, 01 May 2024 | CN¥950.7b | CN¥161.8b | CN¥17.7b | 37.7x | 53.7x | 5.9x |
| Fri, 29 Mar 2024 | CN¥967.6b | CN¥164.6b | CN¥22.0b | 36.6x | 44x | 5.9x |
| Sun, 25 Feb 2024 | CN¥992.7b | CN¥168.7b | CN¥21.7b | 34.6x | 45.8x | 5.9x |
| Tue, 23 Jan 2024 | CN¥951.4b | CN¥167.9b | CN¥21.4b | 33.4x | 44.4x | 5.7x |
| Thu, 21 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.7x | 50.4x | 6.4x |
| Sat, 18 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 41.3x | 52x | 6.6x |
| Mon, 16 Oct 2023 | CN¥1.1t | CN¥170.9b | CN¥25.2b | 44.3x | 43.1x | 6.4x |
| Wed, 13 Sep 2023 | CN¥1.0t | CN¥170.7b | CN¥25.2b | 39.6x | 40.8x | 6x |
| Fri, 11 Aug 2023 | CN¥1.1t | CN¥174.5b | CN¥28.5b | 38.5x | 37.4x | 6.1x |
| Sun, 09 Jul 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 38.6x | 36.1x | 6x |
| Tue, 06 Jun 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 41.7x | 38.2x | 6.3x |
| Thu, 04 May 2023 | CN¥1.2t | CN¥180.9b | CN¥31.8b | 43.4x | 38.5x | 6.8x |
| Sat, 01 Apr 2023 | CN¥1.2t | CN¥186.1b | CN¥36.8b | 40.5x | 33.6x | 6.6x |
| Mon, 27 Feb 2023 | CN¥1.3t | CN¥179.6b | CN¥38.0b | 44.2x | 33.8x | 7.2x |
| Wed, 25 Jan 2023 | CN¥1.3t | CN¥179.6b | CN¥38.0b | 44x | 35.2x | 7.4x |
| Fri, 23 Dec 2022 | CN¥1.2t | CN¥175.6b | CN¥37.9b | 37.1x | 31.3x | 6.8x |
| Sun, 20 Nov 2022 | CN¥1.3t | CN¥175.5b | CN¥37.9b | 41.6x | 34.4x | 7.4x |
| Tue, 18 Oct 2022 | CN¥1.2t | CN¥174.5b | CN¥40.3b | 33.7x | 29.8x | 6.9x |
| Thu, 15 Sep 2022 | CN¥1.2t | CN¥173.8b | CN¥40.0b | 33.9x | 30.2x | 7x |
| Sat, 13 Aug 2022 | CN¥1.3t | CN¥171.9b | CN¥43.3b | 35.8x | 29.5x | 7.4x |
| Mon, 11 Jul 2022 | CN¥1.3t | CN¥168.1b | CN¥42.4b | 38.7x | 31.7x | 8x |
| Wed, 08 Jun 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 37.5x | 28.7x | 7.2x |
| Fri, 06 May 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 34.9x | 29x | 7.3x |
| Sun, 03 Apr 2022 | CN¥1.4t | CN¥153.1b | CN¥41.1b | 42.3x | 35.2x | 9.4x |
| Tue, 01 Mar 2022 | CN¥1.4t | CN¥152.3b | CN¥41.0b | 47.9x | 35.3x | 9.5x |
Price to Earnings Ratio
35.3x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 79.5x which is higher than its 3-year average PE of 44.1x.
- The industry is trading close to its 3-year average PS ratio of 6.5x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 36% per year over the last three years,
- Revenues have also declined 3.5% per year.
- This means overall sales from these companies are declining and profits are subsequently falling as well.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 2.02% | |
| Healthcare | 1.78% | |
| Biotech | 2.06% | |
| Biotech | 2.06% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 300122 Chongqing Zhifei Biological Products | CN¥26.85 | 5.3% +CN¥3.3b | -49.4% | PE17.4x | |
| 300676 BGI Genomics | CN¥65.09 | 12.3% +CN¥2.7b | 48.2% | PS6.2x | |
| 688336 Sunshine Guojian Pharmaceutical (Shanghai) | CN¥26.25 | 15.9% +CN¥2.2b | 13.7% | PE44.5x | |
| 688266 Suzhou Zelgen BiopharmaceuticalsLtd | CN¥74.30 | 9.5% +CN¥1.7b | 64.0% | PS40.3x | |
| 688278 Xiamen Amoytop Biotech | CN¥86.17 | 4.8% +CN¥1.6b | 48.2% | PE47.3x |
